Papua New Guinea

Population 2018  8.6 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>37 (30–45)</td>
<td>432 (352–521)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>2.7 (2.2–3.3)</td>
<td>32 (26–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>2 (1.2–2.9)</td>
<td>23 (14–33)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.5 (3–6.2)</td>
<td>52 (35–72)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.25 (0.1–0.45)</td>
<td>2.8 (1.2–6.2)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed**
- % children aged 0-14 years
- % women
- % men

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018  75% (62–92)

TB/HIV care in new and relapse TB patients, 2018

- % patients with known HIV status who are HIV-positive
- % on antiretroviral therapy

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases
  - Previously treated cases

Laboratory-confirmed cases*  MDR/RR-TB: 433, XDR-TB: 8

Patients started on treatment* **  MDR/RR-TB: 401, XDR-TB: 8

Treatment success rate and cohort size

- New cases registered in 2017
- Previously treated cases registered in 2017
- MDR/RR-TB cases started on second-line treatment in 2016
- XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions)  35

Funding source: 52% domestic, 25% international, 24% unfunded

Notes:
- * Ranges represent uncertainty intervals
- ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
- *** Calculated for pulmonary cases only
- * Includes cases with unknown previous TB treatment history
- ** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2019-10-18 Data: www.who.int/tb/data